Intuitive Has Its Eye on This Newcomer

In the following video, Motley Fool health care bureau chief Brenton Flynn continues his look at Intuitive Surgical's (NASDAQ: ISRG  ) annual report. Specifically, he takes a look at one possible new competitive threat emerging on the company's radar. The company, called IMRIS, has its primary focus on intraoperative MRI technology, but is currently conducting clinical trials for a surgical platform targeting neurological conditions. Brenton tells investors whether this company is a concern and what other competitive threats Intuitive might be facing.

Are stories of Intuitive's demise greatly exaggerated?
Recently, some investors have questioned Intuitive Surgical's future. However, Intuitive Surgical expert Karl Thiel believes a visible path to long-term growth persists. Will Intuitive capitalize, or be crushed by unforeseen pitfalls? His report highlights all of the key opportunities and risks facing the company -- and includes a full year of ongoing updates as key new hits -- so be sure to claim your copy by clicking here now.


Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 24, 2013, at 9:55 AM, BruceBeck wrote:

    IMRS is the one to watch for neuro robotics. Their SYMBIS system (previously called Neuroarm) is the most advanced system for neuro & micro surgery on the market - or will be later this year. SYMBIS system can be used in conjunction with the VISIUS (interoperative MRI) operating suite (iMRI) to guide surgeons in real time on large HD screens just in front of them. This is the first time in history surgeons have the ability to monitor their progress in real time to help facilitate complete removal of tumors on the first attempt - minimizing follow up precedures significantly. This is HUGE cost savings to hospitals but most importantly significantly reduces risks to patients through repeated procedures. This is great news on multiple fronts. iMRIS will be fully moved into its new headquarters in Minneapolis by October 2013.

    iMRIS Inc. (ticker IMRS on Nasdaq).

  • Report this Comment On February 27, 2013, at 5:08 PM, tickertutor wrote:

    Great comment, Bruce! Couldn't have said it any better. 510k FDA application submitted in August 2012. Any idea how much longer before we get a decision?

Add your comment.

DocumentId: 2263169, ~/Articles/ArticleHandler.aspx, 4/24/2014 2:23:13 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement